U.S. flag An official website of the United States government
  1. Home
  2. Tobacco Products
  3. Tobacco Science & Research
  4. Research
  5. FDA and NIH Study: Population Assessment of Tobacco and Health
  1. Research

FDA and NIH Study: Population Assessment of Tobacco and Health

PATH - Population Assessment of Tobacco and Health - A collaboration between the NIH and FDA

The Population Assessment of Tobacco and Health (PATH) Study is a uniquely large, long-term study of tobacco use and health in the United States. A collaboration between the U.S. Food and Drug Administration (FDA) Center for Tobacco Products and the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA), the study was launched in 2011 and started the first wave of data collection in 2013. For updates on PATH Study data collection, see “PATH Study FAQs for Researchers.” 

On this page:

About the PATH Study

By following study participants over time, the PATH Study helps scientists learn how and why people start using tobacco, quit using it, and start using it again after they’ve quit, as well as how different tobacco products affect health (such as cardiovascular and respiratory health) over time. Findings from the study may also inform FDA’s actions related to tobacco products, thereby helping to achieve the goals of the Family Smoking Prevention and Tobacco Control Act.

Andrew Hyland, Ph.D.

Dr. Andrew Hyland, Roswell Park Cancer Institute, Scientific Director of the PATH Study, discusses PATH as part of FDA’s Tobacco Researcher Interviews series.

The PATH Study is conducted via a contract awarded to Westat and involves researchers from:

  • Centers for Disease Control and Prevention 
  • Center for Tobacco Products, FDA
  • Dartmouth College
  • National Institute on Drug Abuse, NIH
  • New York University
  • Roswell Park Cancer Institute
  • Rutgers, The State University of New Jersey
  • Truth Initiative (formerly Legacy)
  • The Medical University of South Carolina
  • The University of California, San Diego
  • The University of Minnesota
  • The University of Waterloo

To learn more, view the “PATH Study 101” video, developed to provide an orientation to the study.

Research Goals for the PATH Study

FDA Tobacco
Education Resource Library

Embed FDA tobacco content on your website for free. Through the FDA Tobacco Education Resource Library, when content is updated on our site, it will automatically update on your site as well.

Embed This Content

By monitoring and assessing behaviors, attitudes, biomarkers, and health outcomes associated with tobacco use in the United States, the PATH Study helps enhance the evidence base available to inform FDA’s regulatory activities related to tobacco. Specifically, the study aims to:

  • Examine what makes people susceptible to using a tobacco product
  • Evaluate initiation and use patterns, including the:
    • use of newer products, such as  e-cigarettes or ENDS (electronic nicotine delivery systems)
    • use of multiple products
    • switching from one product to another
  • Study patterns of tobacco product use, cessation, and relapse
  • Track potential behavioral and health impacts, including biomarkers of exposure and harm
  • Assess differences in tobacco-related attitudes, behaviors, and health conditions among racial/ethnic, gender, and age subgroups

Findings from the PATH Study

About 46,000 people aged 12 years and older, including tobacco users and non-users, are included in the first wave of the PATH Study.

Initial data on adult and youth tobacco use, published January 2017 in the New England Journal of Medicine, showed that more than 25 percent of American adults were current users of tobacco in 2013-14 and roughly 9 percent of youth reported using tobacco in the past 30 days. Multiple product use was common among tobacco users, accounting for roughly 40 percent of adult and youth tobacco users, with cigarettes and e-cigarettes being the most common combination among both age groups.

Among tobacco users who reported using more than one product:

  • 23 percent of adults and 15 percent of youth used cigarettes and e-cigarettes
  • 6 percent of adults and 4 percent of youth used cigarettes and hookah
  • 2 percent of adults and 5 percent of youth used e-cigarettes and hookah
  • 5 percent of adults and 10 percent of youth used cigarettes and cigarillos

The study reports prevalence for more product combinations used by study participants.

Data Access and Availability

Data and documentation (questionnaires, codebooks) related to the PATH Study are available on the National Addiction & HIV Data Archive Program (NAHDAP) website including:

  • PATH Study Data Tables and Figures: Waves 1 - 5 (2013 – 2019)
  • Public-use files (PUFs)from Wave 1 (Sep. 2013–Dec. 2014), Wave 2 (Oct. 2014–Oct. 2015), Wave 3 (Oct. 2015–Oct. 2016), Wave 4 (Dec. 2016—Jan. 2018), and Wave 5 (Dec. 2018–Nov. 2019).
  • Restricted-use files (RUFs)from Wave 1 (Sep 2013–Dec 2014), Wave 2 (Oct 2014–Oct 2015), Wave 3 (Oct 2015–Oct 2016), Wave 4 (December 2016 – Jan 2018), and Wave 5 (Dec. 2018–Nov. 2019), State Design Data, Wave 1 – Wave 5 Tobacco Universal Product Codes, and Wave 2 – Wave 5 State Identifier Data. Qualified researchers are encouraged to apply for access through the NAHDAP website.
  • Biomarker Restricted-use files (BRUFs)from Wave 1 (Sep 2013–Dec 2014), Wave 2 (October 2014 – October 2015), Wave 3 (Oct 2015— 2016), and Wave 4 (December 2016 – January 2018) and Wave 5 (Dec. 2018-Nov. 2019). 
  • Biospecimen Access Program (BAP)which provides the research community with access to urine, serum, and plasma collected from adult PATH Study participants during Wave 1 (Sep. 2013–Dec. 2014).
  • Special Collection Restricted-use files (SCRUFs) from Wave 4.5 Youth Only Data Collection; Wave 5.5 Youth and Young Adults ages 13-19 and the PATH Study Adult Telephone Survey (PATH-ATS), ages 20+
  • Special Collection Public-use files (SCPUFs) from Wave 4.5 Youth Only Data Collection

Researchers interested in the PATH Study are encouraged to create an account to join the PATH Study Data User Forum. The forum enables researchers using PATH Study data to submit and answer questions. Announcements, data releases and updates, new publications, upcoming events, and other information for PATH Study data users are also posted to the forum.

Questions about the collection, content, weighting, documentation, or structure of PATH Study data may be submitted to the new Westat email: [email protected].

NOTE: This email address is not for questions about statistical analysis or analytic guidance. For analytic questions, researchers may wish to consult with statisticians and analysts at their institutions. Additionally, the PATH Study User Forum can be used to obtain feedback and engage in discussion with other PATH Study data users.

PATH Study Publications

Listed below is a selection of peer-reviewed journal articles from the PATH Study. See the NAHDAP website or search PubMed.gov for a complete list of publications.

Note: The following publications are highlighted for illustrative purposes only. The information in these highlighted publications is not a formal dissemination of information by FDA and does not represent agency position or policy. The contents of the publications are the responsibility of the authors alone.

Additional Resources

Subscribe to Spotlight on Science

Stay current on tobacco regulatory science and research, tobacco scientific publications and study findings, CTP grants, and more in this quarterly newsletter.

Back to Top